MARKET

SAVA

SAVA

Cassava Sciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.125
+0.005
+0.16%
Closed 18:48 07/08 EDT
OPEN
3.100
PREV CLOSE
3.120
HIGH
3.340
LOW
3.060
VOLUME
1.66M
TURNOVER
--
52 WEEK HIGH
10.95
52 WEEK LOW
1.030
MARKET CAP
77.44M
P/E (TTM)
-13.4235
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SAVA stock price target is 14.00 with a high estimate of 16.00 and a low estimate of 12.00.

EPS

SAVA News

More
Cassava Sciences: Not Giving Up On Alzheimer's Treatment Yet
Seeking Alpha - Article · 06/16 22:38
Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study Update
GlobeNewswire · 06/16 13:15
Cassava Sciences Added To Russell Indexes And Provides Phase 2b Study Update
AUSTIN, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that the Company will be added to the
Benzinga · 06/16 12:16
Hedge Funds Cautiously Watching Cassava Sciences, Inc. (SAVA)
Insider Monkey · 06/10 21:33
FSD Pharma Jumps On COVID-19 Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 06/05 16:20
AAL, LK, SMAR and SAVA among midday movers
Seeking Alpha - Article · 06/04 16:42
SMAR, CHNG among premarket losers
Seeking Alpha - Article · 06/04 13:17
APPS, SAVA, PGEN and LPI among midday movers
Seeking Alpha - Article · 06/03 16:42

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About SAVA

Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the early detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a small molecule that targets an altered form of a scaffolding protein called filamin A (FLNA). The Company is also developing an experimental biomarker/diagnostic, PTI-125Dx. It is developing PTI-125Dx to detect Alzheimer’s disease with a blood test.
More

Webull offers kinds of Cassava Sciences Inc stock information, including NASDAQ:SAVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SAVA stock methods without spending real money on the virtual paper trading platform.